These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23417780)

  • 1. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.
    Mahlmann A; Gehrisch S; Beyer-Westendorf J
    J Thromb Thrombolysis; 2013 Nov; 36(4):533-5. PubMed ID: 23417780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phamacokinetics of rivaroxaban in adolescents.
    Beyer-Westendorf J; Gehrisch S
    Hamostaseologie; 2014; 34(1):85-7. PubMed ID: 24154682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
    Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
    Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
    Prandoni P; Temraz S; Taher A
    Semin Hematol; 2014 Apr; 51(2):121-30. PubMed ID: 24861796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
    Kreutz R
    Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Mueck W; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Kälebo P; Muelhofer E; Misselwitz F; Eriksson BI
    Thromb Haemost; 2008 Sep; 100(3):453-61. PubMed ID: 18766262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
    Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
    Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
    Kreutz R
    Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.
    Kröll D; Stirnimann G; Vogt A; Lai DLL; Borbély YM; Altmeier J; Schädelin S; Candinas D; Alberio L; Nett PC
    Br J Clin Pharmacol; 2017 Jul; 83(7):1466-1475. PubMed ID: 28121368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Abrams PJ; Emerson CR
    Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.
    Baruch L; Sherman O
    Ann Pharmacother; 2013 Sep; 47(9):1210-2. PubMed ID: 24259738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of thromboembolism in bariatric surgery with parnaparin.
    Forestieri P; Quarto G; De Caterina M; Cuocolo A; Pilone V; Formato A; Ruocco A; Ferrari P
    Obes Surg; 2007 Dec; 17(12):1558-62. PubMed ID: 18004632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.